RxDoctor Payments Data

Hui Wu

Nurse Practitioner · Brooklyn, NYNPI 1790039311

Payments from drug & device makers

$7,463in general payments, 2019–2025

Across 346 payments — averaging $21.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Gilead$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$783
  • Johnson & Johnson$450
  • Madrigal Pharmaceuticals$265
  • Ardelyx, Inc.$159
  • plus $687 from 15 others

What the payments were for

  • Food & beverage$7,463100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,463 in reported general payments places this provider in the 95th percentile of 4,112 nurse practitioner providers in New York.

See all nurse practitioner providers in New York

Medicare billing

Part B allowed, 2024
$6,917
Medicare patients
58
Services billed
66

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VemlidyTenofovir Alafenamide81$112,957
CreonLipase/Protease/Amylase34$52,056
LinzessLinaclotide85$46,282
SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag107$13,167
Sucralfate377$12,198
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C82$10,763
NexiumEsomeprazole Magnesium25$9,128
Omeprazole1,063$8,528
Dexlansoprazole DrDexlansoprazole47$7,943
Entecavir21$7,066
Mesalamine31$5,180
Mesalamine ErMesalamine36$4,485
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl196$3,090
Ursodiol28$2,167
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates27$1,732

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadVemlidy$2,268$112,95781 claims
AbbVieCreon, Linzess$2,851$98,338119 claims
Braintree Laboratories, Inc.Suflave$55$13,167107 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCPlenvu$783$10,76382 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,112 nurse practitioner providers in New York.

Other nurse practitioner in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →